仟源醫藥(300254.SZ)：投資控股子公司擬通過受讓及增資方式收購嘉逸醫藥51%股權
格隆匯11月15日丨仟源醫藥(300254.SZ)公佈，2019年11月15日，公司第三屆董事會第三十六次會議審議通過了《關於投資控股子公司暨受讓江蘇嘉逸醫藥有限公司部分股權並對其增資的議案》。
公司與醴澤基金、張宇簽署《關於投資江蘇嘉逸醫藥有限公司之合作協議》，共同投資(增資)特殊目的公司南通恆嘉藥業有限公司(“SPV公司”)，註冊資本為人民幣約3.72億元，其中公司以自有資金出資約1.56億元，持股42%；醴澤基金出資約1.08億元，持股29%；張宇出資約1.08億元，持股29%。
公司、SPV公司與JOY GLORY INVESTMENT LIMITED嘉逸投資有限公司(HongKong)(“嘉逸投資”)、黃樂羣先生、嘉逸醫藥共同簽署《股權轉讓協議》，SPV公司以人民幣3.43億元交易價格受讓嘉逸醫藥49%股權。股權轉讓協議中約定黃樂羣先生將通過二級市場增持仟源醫藥不超過5%的股份。
SPV公司與嘉逸投資簽署《關於江蘇嘉逸醫藥有限公司之增資協議》，待SPV公司受讓嘉逸醫藥49%股權辦理完成相應的工商變更登記及完成支付股權轉讓價款後SPV公司向嘉逸醫藥增資人民幣2857.14萬元，增資完成後SPV公司將持有嘉逸醫藥51%股權。
嘉逸醫藥是一家集藥品研發、生產和銷售為一體的企業，其擁有14項發明專利或實用新型專利，30項藥品臨牀批件，並有鹽酸西那卡塞、利伐沙班、酒石酸伐尼克蘭、阿哌沙班、安立生坦等5個產品取得申報生產(一致性評價)受理，鹽酸西那卡塞和酒石酸伐尼克蘭被納入優先審評。
此次投資控股子公司暨受讓嘉逸醫藥部分股權並對其增資符合公司在醫藥領域的發展戰略，黃樂羣先生及嘉逸醫藥團隊的加入，將極大提升公司整體藥品研發水平及創新能力；嘉逸醫藥研發和生產的藥品有較大的市場前景，有助於快速擴展並完善公司的產品結構，增強公司的市場競爭力和抗風險能力，不斷提升公司盈利能力和可持續發展能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
